Ionis Pharmaceuticals EVP Joseph Baroldi Purchases Company Shares
Ionis Pharmaceuticals EVP Joseph Baroldi bought 5,635 shares valued at $277,181.14.
Key Points
- Joseph Baroldi, EVP at Ionis Pharmaceuticals, bought 5,635 shares worth $277,181.14 on June 26.
- Ionis Pharmaceuticals, trading near $80.69, has a market cap of about $13.4 billion and a 52-week high of $86.74.
- Analyst firms like Leerink Partners and HC Wainwright maintain a 'buy' rating with targets up to $130.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Joseph Baroldi, Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), made a significant purchase of company shares. On June 26, Baroldi bought 5,635 shares at an average price of $49.19, totaling approximately $277,181. This transaction was not part of a 10b5-1 trading plan.
Insider Buying and Selling at Ionis Pharmaceuticals, Inc.
In addition to Joseph Baroldi's purchase, several other insider transactions took place on June 26. Eugene Schneider, EVP and Chief Clinical Development Officer, bought 26,000 shares at $60.89 and sold an equivalent amount at $81.05 under a planned sale. Patrick O'Neil, EVP CLO & General Counsel, sold 3,069 shares at $80.00, also under a planned sale.
Ionis Pharmaceuticals, Inc. Stock Up 31.4%
Shares of Ionis Pharmaceuticals traded near $80.69 on Wednesday. The company, with a market cap of about $13.4 billion, operates in the biotechnology sector. It has a 52-week low of $39.37 and a high of $86.74, with a 50-day moving average of $75.05. Ionis has a current ratio of 4.10 and a quick ratio of 2.86, but its forward P/E ratio isn't meaningful due to negative earnings.
$IONS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Ionis Pharmaceuticals. On June 25, Goldman Sachs maintained a 'hold' rating with a price target of $75. Leerink Partners and HC Wainwright & Co. both maintained 'buy' ratings, with price targets of $129 and $130, respectively. The consensus recommendation remains a 'buy', with a mean target price of $105.91 based on 23 analyst opinions.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. It focuses on developing RNA-targeted medicines for various diseases. The company offers treatments for conditions like spinal muscular atrophy, hereditary angioedema, and amyloidosis. It also has a robust pipeline of products in clinical trials and strategic collaborations with major pharmaceutical firms like Biogen, GSK, and AstraZeneca. Ionis was founded in 1989 and is led by CEO Dr. Brett P. Monia.
Bottom Line
The purchase by Joseph Baroldi underscores insider confidence in Ionis Pharmaceuticals' prospects. Investors often monitor insider transactions as potential indicators of a company's future performance. However, it's important to remember that such filings reflect past transactions and may not indicate current positions or future intentions.
Get Ionis Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IONS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.